Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangzhou Baiyunshan Pharmaceutical Holdings CoFRA:GU5 -1.32%70 Earnings Yield (Joel Greenblatt) % is 8.77% as of Jun. 2026, which is 8% below its 10-year median of 9.49. GuruFocus rates FRA:GU5 with a GF Score™ of 70/100 and a GF Value™ of €2.22 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 123 Medical Distribution companies, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks better than 61.79% on this metric.
FRA:GU5's Earnings Yield (Joel Greenblatt) % is ranked better than 61.79% of 123
companies
in the Medical Distribution industry
Industry Median: 6.19
vs FRA:GU5: 9.00
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Guangzhou Baiyunshan Pharmaceutical Holdings Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was -0.56%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Earnings Yield (Joel Greenblatt) % vs Medical Distribution Industry
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €449 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 8.77% mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Earnings Yield (Joel Greenblatt) % of 8.77% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. This is near median its historical median of 9.49. Over the past decade, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % has ranged from 5.55 to 16.04. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #47 out of 123 companies in the Medical Distribution industry, placing it in the top 38.2%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Earnings Yield (Joel Greenblatt) % of 8.77% is near median its 10-year median of 9.49. Over the past 10 years, this metric has ranged from a low of 5.55 to a high of 16.04. The Medical Distribution industry median Earnings Yield (Joel Greenblatt) % is 6.19. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 8.77% is 41.7% above this industry median. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #47 out of 123 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #47 out of 123 companies for Earnings Yield (Joel Greenblatt) %. This puts Guangzhou Baiyunshan Pharmaceutical Holdings Co in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 6.19. Guangzhou Baiyunshan Pharmaceutical Holdings Co's value of 8.77% is 41.7% above this benchmark. Historically, Guangzhou Baiyunshan Pharmaceutical Holdings Co's own Earnings Yield (Joel Greenblatt) % has ranged from 5.55 to 16.04 over the past decade. While the company's 10-year median is 9.49 vs. the industry median of 6.19, Guangzhou Baiyunshan Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Distribution company?
The median Earnings Yield (Joel Greenblatt) % among Medical Distribution companies is 6.19, based on 123 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Earnings Yield (Joel Greenblatt) % of 8.77% is 41.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median Earnings Yield (Joel Greenblatt) % is 6.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Earnings Yield (Joel Greenblatt) % is 8.77%, which is near median its own 10-year median of 9.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.22, compared to a current price of €1.49 — trading 32.9% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 8.77%, which is near median its 10-year median of 9.49 and 41.7% above the Medical Distribution industry median of 6.19. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Earnings Yield (Joel Greenblatt) % is 8.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.49 is trading 32.9% below its estimated GF Value™ of €2.22.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for FRA:GU5:
Earnings Yield (Joel Greenblatt) %: 8.77% (near median its 10-year median of 9.49)
GF Value™: €2.22 vs. price of €1.49 (32.9% below fair value)
Industry Position: 41.7% above the Medical Distribution median (#47 of 123)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
70GF Score
Get the complete analysis for FRA:GU5
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
